Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
2019 · New England Journal of Medicine · 2,479 citations
https://doi.org/10.1056/nejmoa1816047
W
Wilson H. Miller
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
612
Papers
44.4K
Citations
80
h-index
244
i10-index
Wilson H. Miller is an academic researcher from Jewish General Hospital. The author has contributed to research in topics: Retinoids in leukemia and cellular processes & Cancer Immunotherapy and Biomarkers & Acute Myeloid Leukemia Research. The author has an h-index of 80, co-authored 521 publications.
ORCID: 0000-0002-7408-1574Papers by this author
worksAssociation of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
2020 · The Lancet Oncology · 2,390 citations
https://doi.org/10.1016/s1470-2045(20)30445-9
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
2017 · Journal of Clinical Oncology · 617 citations
https://doi.org/10.1200/jco.2016.67.9258
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
2023 · Nature Medicine · 385 citations
https://doi.org/10.1038/s41591-023-02453-x
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
2011 · British Journal of Cancer · 88 citations
https://doi.org/10.1038/bjc.2011.402
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
2020 · Nature Communications · 86 citations
https://doi.org/10.1038/s41467-020-19810-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat